ReviewMicrobiology spectrum2016
Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.
Review in Microbiology spectrum, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 154 citations in OpenAlex.
- Association of Toll-like 4 receptor gene polymorphism (rs4986790, rs4986791) with the risk of urinary tract infection: A systematic review and meta-analysis.The Kaohsiung journal of medical sciences · 2020Pooled it
- Effects of emergency/nonemergency cervical cerclage on the vaginal microbiome of pregnant women with cervical incompetence.Frontiers in cellular and infection microbiology · 2023Trial
- Limited effects of long-term daily cranberry consumption on the gut microbiome in a placebo-controlled study of women with recurrent urinary tract infections.BMC microbiology · 2021Trial
- Preventive strategies for recurrent urinary tract infections in premenopausal women: A scoping review.The European journal of general practice · 2026Article
- Uropathogenic Escherichia coli invade luminal prostate cells via FimH-PPAP receptor binding.Nature microbiology · 2026Article
- Chimeric vaccine based on Iraqi HLA alleles against a predominant localFrontiers in immunology · 2026Article
- Uncovering the Hidden Diversity and Antimicrobial Resistance of Uropathogens in a Tertiary-Care Hospital in Bangladesh.International journal of microbiology · 2026Article
- Current Scientific Advances in Vaccines Against UTIs: Challenges and Prospects.Microorganisms · 2025Review
- Uropathogenic Escherichia coli niche occupancy determines the effects of mucosal vaccine against FimH.Cell reports · 2025Article
- Bladder p75Life (Basel, Switzerland) · 2025Article
- Analysis of the Distribution Characteristics and Changes of Drug Resistance of Pathogens in Patients with Urinary Tract Infection Across Southwest China From 2019 to 2023.Infection and drug resistance · 2025Article
- Immunogenic Potential of a Multi-Peptide Vaccine Construct Against Uropathogenic Escherichia coli-Associated Urinary Tract Infection.Iranian biomedical journal · 2024Article
- Effect of free liquid layer quantity on bacteria and protein adhesion to liquid infused polymers.Biointerphases · 2024Article
- Secondary Analysis of Interstitial Cystitis/Bladder Pain Syndrome Patients Enrolled in a Recurrent Urinary Tract Infection Prevention Study Provides a Novel Paradigm for Etio-Pathogenesis and Practical Management of This Infection Phenotype.Pathogens (Basel, Switzerland) · 2024Article
- Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenicMicrobiology spectrum · 2024Article
- Effect of Mannan Oligosaccharides Extracts in UropathogenicPathogens (Basel, Switzerland) · 2023Article
- Urinary Tract Infections Caused by UropathogenicInternational journal of molecular sciences · 2023Review
- MV140 mucosal bacterial vaccine improves uropathogenicResearch square · 2023Article
- Effect of bovine lactoferrin on recurrent urinary tract infections: in vitro and in vivo evidences.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- An Effective Sublingual Vaccine, MV140, Safely Reduces Risk of Recurrent Urinary Tract Infection in Women.Pathogens (Basel, Switzerland) · 2023Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Urinary tract infections (UTI) are among the most common bacterial infections in humans, affecting millions of people every year. UTI cause significant morbidity in women throughout their lifespan, in infant boys, in older men, in individuals with underlying urinary tract abnormalities, and in those that require long-term urethral catheterization, such as patients with spinal cord injuries or incapacitated individuals living in nursing homes. Serious sequelae include frequent recurrences, pyelonephritis with sepsis, renal damage in young children, pre-term birth, and complications of frequent antimicrobial use including high-level antibiotic resistance and Clostridium difficile colitis. Uropathogenic E. coli (UPEC) cause the vast majority of UTI, but less common pathogens such as Enterococcus faecalis and other enterococci frequently take advantage of an abnormal or catheterized urinary tract to cause opportunistic infections. While antibiotic therapy has historically been very successful in controlling UTI, the high rate of recurrence remains a major problem, and many individuals suffer from chronically recurring UTI, requiring long-term prophylactic antibiotic regimens to prevent recurrent UTI. Furthermore, the global emergence of multi-drug resistant UPEC in the past ten years spotlights the need for alternative therapeutic and preventative strategies to combat UTI, including anti-infective drug therapies and vaccines. In this chapter, we review recent advances in the field of UTI pathogenesis, with an emphasis on the identification of promising drug and vaccine targets. We then discuss the development of new UTI drugs and vaccines, highlighting the challenges these approaches face and the need for a greater understanding of urinary tract mucosal immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.